Uromed, Implant Sciences Join Prostate Cancer Brachytherapy Free-For-All
This article was originally published in The Gray Sheet
Executive Summary
Uromed and Implant Sciences are the most recent entries into the rapidly growing market for prostate-brachytherapy seeds, estimated at $150 mil. in 1999.